Global Ovarian Cancer Diagnostic Market

Ovarian Cancer Diagnostic Market Size, Share, Growth Analysis, By Type(Epithelial tumours, germ cell tumours, stromal tumours), By End user(Hospital Laboratories, diagnostic centres, Research Institutes, others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35F2014 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 64 | Figures: 75

Ovarian Cancer Diagnostic Market Insights

Global Ovarian Cancer Diagnostic Market size was valued at USD 1.57 billion in 2019 and is poised to grow from USD 1.77 billion in 2023 to USD 9.67 billion by 2031, growing at a CAGR of 23.7% in the forecast period (2024-2031).

Ovarian cancer is a type of cancer that occurs in the ovaries; there are several types of ovarian cancer, the most common of which is epithelial ovarian cancer. The primary cause of this type of cancer is uncontrollable cell growth in the ovarian tissue, and it is one of the leading causes of death in women worldwide. It is the fifth most common cause of cancer death in women worldwide, and the tenth most common cause of cancer death in women in the United States. Novel approaches in ovarian cancer treatment is the major factor escalating the market expansion, also increased funding for cancer research, rising in health awareness and increase in aged women population all over the world are the most common factors among others that driving the ovarian cancer diagnostics market. The development and technical advancements in the machines that are used for the treatment can create new opportunities for ovarian cancer diagnostics market in the forecasted period.

Government and research department are focusing on advanced cancer diagnostic methods that could detect the cancer at its early level as the cancer diagnostic methods of present detect the cancer when it has already spread at an advanced level. Rising awareness, increasing focus of government, researchers and other medical organizations to provide convenient and in-time diagnosis of ovarian cancer method are key factors for boosting the market growth.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Ovarian Cancer Diagnostic Market size was valued at USD 1.57 billion in 2019 and is poised to grow from USD 1.77 billion in 2023 to USD 9.67 billion by 2031, growing at a CAGR of 23.7% in the forecast period (2024-2031).

ovarian cancer diagnostics market is highly competitive and fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, acquisitions, co-development deals, product launches & development, collaborations and partnerships are adopted by these players to thrive in the competitive market. The most recent advancements in ovarian cancer diagnostics are desperately needed in the industry to detect cancer in its early stages and treat it without causing significant damage to the affected person's internal organs. Top ovarian cancer diagnosis instrument manufacturers are investing in research and development of devices and instruments that will aid in the diagnosis and treatment of ovarian cancer more effectively and efficiently. 'Abbott Laboratories', 'Roche', 'Quest Diagnostics', 'Siemens Healthineers', 'Thermo Fisher Scientific', 'Becton, Dickinson and Company (BD)', 'bioMérieux SA', 'Hologic, Inc.', 'Illumina, Inc.', 'Myriad Genetics, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Genomic Health, Inc.', 'Agilent Technologies', 'AstraZeneca', 'Bio-Rad Laboratories, Inc.', 'GE Healthcare', 'Merck KGaA', 'NanoString Technologies', 'Oncocyte Corporation', 'PerkinElmer Inc.'

Increase in the number of elderly women is driving the ovarian cancer diagnostics market. The growing elderly female population leads to the increase in the chances of infected ovarian cancer. This increase in population has the potential to drive the ovarian cancer diagnostics market. As a result, governments launch initiatives to expand health care and treatment.

The increased understanding of certain cancer biomarkers is gaining a commercial opportunity for treating cancer patients through developed detection technology and equipment. Technological advances in the field of biotechnology have enabled the identification of potential cancer biomarkers, and some of these biomarkers have been commercialised. As a result, the development of new diagnostic biomarkers is opening up lucrative opportunities for the growth of the ovarian cancer diagnostics market.

North America accounted for more market value growth this is because of strong commercial performances of gynecologic diagnostics in the United States. Other factors contributing to the growth of the market in this region include favourable government initiatives, increase in healthcare expenditure, and presence of key manufacturers.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Ovarian Cancer Diagnostic Market

Report ID: SQMIG35F2014

$5,300
BUY NOW GET FREE SAMPLE